The role of trabectedin in soft tissue sarcoma
T Nakamura, A Sudo - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Systemic chemotherapy for advanced disease is another therapeutic option in
the management of metastases in soft tissue sarcoma (STS). Doxorubicin either alone or in …
the management of metastases in soft tissue sarcoma (STS). Doxorubicin either alone or in …
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to …
A Merlini, ML Centomo, G Ferrero, G Chiabotto… - Frontiers in …, 2022 - frontiersin.org
Background Advanced and unresectable bone and soft tissue sarcomas (BSTS) still
represent an unmet medical need. We demonstrated that the alkylating agent trabectedin …
represent an unmet medical need. We demonstrated that the alkylating agent trabectedin …
Alteration of the nucleotide excision repair (NER) pathway in soft tissue sarcoma
A Pasqui, A Boddi, DA Campanacci… - International Journal of …, 2022 - mdpi.com
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are
unluckily restricted to a small subgroup of patients. Much of the inter-individual variability in …
unluckily restricted to a small subgroup of patients. Much of the inter-individual variability in …
A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin
DS Moura, M Peña‐Chilet… - Molecular …, 2021 - Wiley Online Library
Predictive biomarkers of trabectedin represent an unmet need in advanced soft‐tissue
sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination …
sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination …
Integration of serum metabolomics into clinical assessment to improve outcome prediction of metastatic soft tissue sarcoma patients treated with trabectedin
G Miolo, E Di Gregorio, A Saorin, D Lombardi… - Cancers, 2020 - mdpi.com
Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers with few
diagnostic or prognostic biomarkers. This metabolomics study aimed to identify new serum …
diagnostic or prognostic biomarkers. This metabolomics study aimed to identify new serum …
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis
T Imai, Y Kojima, T Shimoi, H Aiba… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Trabectedin is used as a treatment for advanced-stage soft tissue
sarcomas (STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect …
sarcomas (STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect …
Etude des mécanismes impliqués dans l'hépato-toxicité des médicaments anti-cancéreux: exemples de la trabectedine et des inhibiteurs de tyrosine kinases
M Maillard - 2021 - theses.hal.science
Le rôle essentiel du foie dans le métabolisme des médicaments l'expose constamment à
des molécules au potentiel hépatotoxique important ou capables d'être biotransformées en …
des molécules au potentiel hépatotoxique important ou capables d'être biotransformées en …
Analysis of inflammatory biomarkers as predictors of treatment efficacy in patients with soft tissue sarcoma treated with trabectedin
Background: Trabectedin is used as a treatment for advanced-stage soft tissue sarcomas
(STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect on tumor …
(STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect on tumor …
Alessandra Merlini1, 2†, Maria Laura Centomo 1, 2†, Giulio Ferrero 3, 4, Giulia Chiabotto5, Umberto Miglio1, Enrico Berrino1, 5, Giorgia Giordano1, 2, Silvia Brusco1 …
G Crisafulli, M Aglietta, AP Dei Tos… - … , and Other Marine …, 2023 - books.google.com
Background: Advanced and unresectable bone and soft tissue sarcomas (BSTS) still
represent an unmet medical need. We demonstrated that the alkylating agent trabectedin …
represent an unmet medical need. We demonstrated that the alkylating agent trabectedin …
A metabolomics approach to predict trabectedin pharmacokinetic and pharmacodynamic variability in advanced soft tissue sarcoma patients
E Di Gregorio - 2022 - dspace.unive.it
La trabectidina è utilizzata con successo per i pazienti con sarcomi dei tessuti molli (STS)
avanzati o metastatici. Tuttavia, si osserva ancora una grande variabilità nella risposta …
avanzati o metastatici. Tuttavia, si osserva ancora una grande variabilità nella risposta …